Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TM-Uprise Study of nivolumab plus TM5614 in previously treated non-small cell lung cancer
jRCT2061230039Phase 2Active, not recruiting
- Sponsor
- Renascience
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and TM5614 in non-small cell lung cancer (NSCLC), sponsored by Renascience. Primary endpoint: Objective response rate. Started Sep 2023; status: active, not recruiting.
02
Drugs
nivolumabTM5614
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2061230039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061230039.